Abstract 2505
Background
Worldwide, according to WHO 2014, over 19 million patients are in need of palliative care, 34% of them will die of cancer. Palliative care research brings many challenges. This metaresearch study aims to evaluate how clinical research on palliative care is conducted within the setting of incurable cancer.
Methods
Clinicaltrials.gov was searched to identify all registered studies investigating palliative care in patients with advanced or metastatic cancer. The EORTC QLQ-C15-PAL questionnaire was used to define the domains of interest. We excluded studies investigating cancer-directed therapy, management of cancer treatment-related adverse events, and diagnostic tests. Publication status was crosschecked using PubMed.
Results
Of 3950 identified studies, 514 studies were included. The most frequent reason for exclusion was cancer-directed therapy (2491). In 2007-2012, 161 studies were registered vs 245 in 2013-2018. Included studies were interventional (84%, 430/514) or observational (16%, 84/514). Most studies were sponsored by academia (79%), and conducted in North America (57%) or Europe (25%). 67% of studies evaluated a heterogeneous population (any tumour type). 60% were monocentric studies. Interventional studies most frequently investigated systemic drugs (34%, 148/430), behavioural interventions (29%, 125/430), and procedures for pain (24%, 103/430). Pain, quality of life and physical function were the most studied palliative issues (188, 95, 52 studies respectively). Fewer studies investigated health care planning (45), emotional function (35), appetite (22), social function (22), fatigue (20), dyspnea (18), sleep disturbance (5), cognitive function (5), nausea (4), and constipation (3). The most applied primary outcome measures were efficacy/symptom control (61.5%, 316), quality of life (14.2%, 73) and feasibility (11.7%, 60). Only 16% of the closed studies had published results.
Conclusions
The studies investigating palliative care in patients with incurable tumours constitute a very small part of cancer clinical research. More than one third of studies examine pain, leaving other palliative issues less explored in clinical research. Furthermore, the results of these studies are under reported in the literature.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2728 - MicroRNA expression and DNA methylation profiles do not distinguish between primary and recurrent well-differentiated liposarcoma
Presenter: Melissa Vos
Session: Poster Display session 1
Resources:
Abstract
3197 - Genomic Alterations, Tumor Mutation Burden and Prognosis of Chinese Cardiac Sarcoma Patients
Presenter: Na Zhu
Session: Poster Display session 1
Resources:
Abstract
4214 - Evaluation of a peptide-conjugated alkylator melflufen in osteosarcoma preclinical models
Presenter: Konstantin Byrgazov
Session: Poster Display session 1
Resources:
Abstract
2654 - Expression analysis of NHEJ and HR genes in Ewing sarcomas: indications of DSB repair dysfunction
Presenter: Anastasios Kyriazoglou
Session: Poster Display session 1
Resources:
Abstract
4383 - Epidemiology of Synovial Sarcoma in EU28 countries
Presenter: Nedra Joseph
Session: Poster Display session 1
Resources:
Abstract
1937 - Resection Of High-Grade Large Soft Tissue Sarcoma With Adequate Wide Margin Can Lead To Good Local Control Without Adjuvant Radiotherapy
Presenter: Toshiyuki Kunisada
Session: Poster Display session 1
Resources:
Abstract
3757 - Influence of eribulin on proliferation, migration and invasion properties of leiomyosarcoma cell line models
Presenter: Marta Mendiola
Session: Poster Display session 1
Resources:
Abstract
1040 - EREMISS: Efficacy of regorafenib (REG) as maintenance therapy in non-adipocytic soft tissue sarcomas (STS) having received 1st-line doxorubicin-based chemotherapy (Doxo-CT)
Presenter: Nicolas Penel
Session: Poster Display session 1
Resources:
Abstract
1048 - A Phase 2 biomarker-driven study evaluating the clinical efficacy of an MDM2 inhibitor, milademetan, in patients with intimal sarcoma, a disease with a high unmet need
Presenter: Kan Yonemori
Session: Poster Display session 1
Resources:
Abstract
1511 - A pilot study of oral paclitaxel (ORAXOL) in subjects with cutaneous angiosarcomas (KX-ORAX-010)
Presenter: Herbert Loong
Session: Poster Display session 1
Resources:
Abstract